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**Why carry out this study?** The study was carried out to determine the utility of obtaining chest X-ray (CXR) in the workup of patients with uveitis. The study aims to correlate pre-test probability with diagnostic yield of CXR in the context of demographic variables such as ethnicity.**What was learned from the study?** The incidence of sarcoidosis is low in our population and CXR was most likely to yield positive results in black patients. Patient demographics should be taken into consideration when ordering laboratory and imaging tests in the workup of uveitis.

Introduction {#Sec1}
============

Uveitis is a broad group of inflammatory diseases of the choroid, ciliary body, and/or iris, though nearly all ocular structures may be affected. It may be categorized by location (e.g., anterior, intermediate, posterior, pan), duration (e.g., acute, chronic, recurrent), and etiology (e.g., autoimmune, neoplastic, or infectious) \[[@CR1]\].

The incidence of uveitis varies widely across different ethnic/racial groups and by geographic location, ranging from 17 to 52 per 100,000 people each year \[[@CR2]\]. In a presumably comparable Western United States population (Northern California) to the population presented in our study, the incidence of uveitis is 52.4 per 100,000 person-years \[[@CR3]\]. Despite its low incidence, uveitis causes 30% of new cases of legal blindness every year in the USA \[[@CR4]\].

Sarcoidosis is a systemic granulomatous inflammatory disease with multiple ocular manifestations. In the eye it most often presents as anterior uveitis, with symptoms of eye pain, photophobia, and blurred vision, and exam findings of anterior chamber cell with granulomatous "mutton fat" keratoprecipitates. It is also known to cause posterior segment involvement including vitreous inflammation and granulomas of the choroid and optic nerve.

Systemic sarcoidosis is the leading cause of interstitial lung disease in developed countries \[[@CR5]\]. It also affects the heart, liver, nervous system, lymphatics, and skin. About half of patients with systemic sarcoidosis will eventually develop ocular involvement \[[@CR6]\]. Sarcoid uveitis may occur in the absence of other systemic disease, or may be the sentinel event that leads to the diagnosis of systemic disease.

Just as the epidemiology of uveitis varies across demographic groups, sarcoidosis varies to an even greater extent. Japan reports only 3.7 cases of sarcoidosis per 100,000 people per year, compared to 28.2 per 100,000 in Finland. While the incidence of sarcoidosis is low in Japan, the proportion of ocular involvement is rather high, ranging from 50% to 93% \[[@CR7], [@CR8]\]. In Sweden 0% of sarcoidosis cases are found in black patients, in contrast to the USA where black patients account for 66% of all sarcoidosis \[[@CR6]\]. In the USA, black patients with sarcoidosis are 13.8 times more likely to have ocular involvement than all other racial/ethnic groups \[[@CR9]\]. These differences are important to account for, especially in our patient population. Only 4.6% of the Colorado population is black, compared with 13.4% in the USA \[[@CR10], [@CR11]\].

The gold standard for diagnosis of sarcoidosis is tissue biopsy showing non-caseating granulomatous inflammation; however, ocular biopsy is rarely performed. Rather, a combination of clinical signs, laboratory testing, and imaging studies is used. Specific criteria were established in 2009 by the International Workshop on Ocular Sarcoidosis and revised in 2019 \[[@CR12], [@CR13]\].

Among the laboratory tests used in the workup of sarcoid uveitis are serum angiotensin-converting enzyme (ACE), serum lysozyme, and soluble serum interleukin-2 receptor. Standard chest imaging is by chest X-ray (CXR) but may also include chest computerized tomography (CT) in certain circumstances. The purpose of this study was to determine the utility of a screening CXR in patients with uveitis seen in the Department of Ophthalmology at the University of Colorado School of Medicine.

Methods {#Sec2}
=======

A retrospective chart review was conducted for patients with uveitis seen at the University of Colorado Department of Ophthalmology by one of two uveitis specialists between January 1, 2011 and July 31, 2017. Standardization of uveitis nomenclature \[[@CR12]\] was used to categorize uveitis by location and duration. The presence or absence of previously established etiology/systemic disease was noted. Laboratory and imaging results were collected from 6 months before or after the initial visit with a uveitis specialist. This included serum ACE and lysozyme as well as CXR and chest CT results. Chest imaging was considered positive if bilateral hilar adenopathy was present. Syphilis serology was obtained on patients without a previously defined etiology. Colorado is not an endemic area for tuberculosis (TB) and the positive predictive value of TB skin testing and Quantiferon in patients with uveitis is 1% and 11%, respectively \[[@CR14]\]. Thus, TB testing was not routinely performed in our study. The Colorado Multiple Institutional Review Board granted approval for access to patient charts for the purposes of data collection as pertains to our study.

All statistics reported in the study were calculated using Microsoft Excel Version 16.37, 2020. Relative risk, sensitivity, and specificity were calculated via a chi-square test to analyze categorical variables.

Results {#Sec3}
=======

Five hundred fifty-nine patients with uveitis presented for an initial visit between January 1, 2011 and July 31, 2017. The majority (58.3%) were female. White patients comprised the largest percentage of the population (44.3%), followed by black patients (15.7%), Latinos (12.5%), and Asians (2.5%). Race was unable to be determined in 24.7%. Almost half (49.2%) of uveitis cases were categorized as anterior; 17.5% were intermediate, 16.8% were panuveitis, and 16.5% were posterior. One third (33%) were acute (new onset) presentations of uveitis. The rest of the cases were chronic (45%) or recurrent (22%). The prevalence of sarcoidosis in our population was 4.3%. Table [1](#Tab1){ref-type="table"} further delineates this data in patients with or without a previous diagnosis of sarcoidosis. Patients designated as having sarcoidosis either had a previous positive biopsy or met the International Workshop on Ocular Sarcoidosis (IWOS) 2019 criteria for presumed ocular sarcoidosis \[[@CR13]\].Table 1Patient characteristics with and without sarcoidosisTotal populationPreviously diagnosed sarcoidosisNo history of sarcoidosisTotal55919540Gender Male231 (41.3%)7 (37%)224 (41.5%) Female328 (58.7%)12 (63%)316 (58.5%)Age Average46.849.946.7 0--39210 (37.6%)5 (26%)205 (38.0%) 40--64228 (40.8%)12 (63%)216 (40.0%) \> 65121 (21.6%)2 (11%)119 (22.0%)Race/ethnicity White248 (44.4%)4 (21%)244 (45.2%) Black87 (15.6%)12 (63%)75 (13.9%) Hispanic72 (12.9%)2 (11%)70 (13.0%) Asian14 (2.5%)0 (0%)14 (2.6%) Unknown138 (24.7%)1 (5%)137 (25.4%)Location of uveitis Anterior275 (49.2%)7 (36.8%)268 (49.6%) Intermediate98 (17.5%)3 (15.8%)95 (17.6%) Posterior92 (16.5%)1 (5.3%)91 (16.9%) Panuveitis94 (16.8%)8 (42.1%)86 (15.9%)Chest X-ray Total performed2049195 Positive12 (5.9%)7 (78%)5 (2.6%) Negative192 (94.1%)2 (22%)190 (97.4%)Chest CT Total performed41635 Positive8 (19%)4 (67%)4 (11%) Negative33 (81%)2 (33%)31 (89%)

Of the 559 patients presenting with uveitis, 204 underwent CXR for evaluation of an undefined etiology for the inflammation. Patients with a defined uveitis syndrome and those with well-defined phenotypes, such as HLA-B27-associated anterior uveitis, did not receive chest imaging. Twelve CXRs revealed bilateral hilar adenopathy, five of which were previously undiagnosed cases of sarcoidosis. This yields a discovery rate of 2.6%. As shown in Table [2](#Tab2){ref-type="table"}, there were 12 positive CXRs, 11 of which were in black patients (this includes new and previously known diagnoses). Of the five new diagnoses of sarcoidosis made in our study, four were in black patients, yielding an 18-fold relative risk. Three of the newly diagnosed patients presented with anterior uveitis and two presented with intermediate uveitis. Two patients with history of biopsy-confirmed sarcoidosis had negative CXR.Table 2Patient characteristics associated with positive chest imagingPositive chest X-rayPositive chest CTTotal128Gender Male4 (25%)2 (25%) Female8 (75%)6 (75%)Age Average52.657.4Race/ethnicity White1 (8%)2 (25%) Black11 (92%)6 (75%) Hispanic00 Asian00 Unknown00Location of uveitis Anterior6 (50%)3 (37.5%) Intermediate4 (33%)3 (37.5%) Posterior00 Panuveitis2 (17%)2 (25%)

Forty-one chest CT scans were performed, eight of which revealed bilateral hilar adenopathy. All eight patients with positive chest CTs had a previous positive CXR, but CT scan was recommended by the radiologist. Four of these positive CT scans were in patients with previous diagnoses of sarcoidosis. Six patients had both positive CXR and positive chest CT. Notably, our study did not identify any patients with a negative CXR and positive chest CT, nor were there any patients with positive CXR and negative chest CT. However, 19 patients with negative CXR underwent subsequent CT on the basis of the recommendation of the radiologist for uncertain findings on CXR. None of these patients were ultimately diagnosed with sarcoidosis or any other meaningful lung pathology.

Serum ACE was obtained in 199 patients. As shown in Table [3](#Tab3){ref-type="table"}, 13 patients had elevated ACE; however, only six of these had sarcoidosis (including patients newly diagnosed in our study). This yields a sensitivity of 31% and specificity of 96%.Table 3Sensitivity and specificity of serum angiotensin-converting enzyme (ACE) and lysozymeSarcoidosisNo sarcoidosisSensitivitySpecificityPositive predictive valueNegative predictive valueACE Total1318631%96%31%96% Positive6 (46%)7 (3.8%) Negative7 (54%)179 (96.2%)Lysozyme Total512160%74%9%98% Positive3 (60%)31 (25.6%) Negative2 (40%)90 (74.4%)

Serum lysozyme was obtained in 126 patients. Table [3](#Tab3){ref-type="table"} shows that 34 patients had elevated lysozyme, although only three of these patients had sarcoidosis. This yields a sensitivity of 60% and specificity of 74%. Notably, positive predictive value is 9% and negative predictive value is 98%.

Discussion {#Sec4}
==========

Our study reveals several important trends regarding the workup of uveitis in the Western United States. Regional population differences affect the diagnostic yield of certain tests, with sarcoidosis being a prime example. Similarly, we did not perform routine TB testing in our patients because of low incidence in Colorado; however we believe it is appropriate to test for TB in select groups such as those with high exposure risk or those starting systemic immunosuppression. Only 4.5% of the Colorado population is black, yet black patients accounted for 15.7% of new uveitic presentations in our study. Despite representing a small portion of the population, 63% of patients with known sarcoidosis were black, and 11 of 12 patients with positive CXR were black. Additionally, four of the five patients with a new diagnosis of sarcoidosis were black.

We are unable to calculate the sensitivity or specificity of CXR or chest CT in our study because the majority of patients with previously diagnosed sarcoidosis did not undergo biopsy to confirm the diagnosis. Rather, diagnoses were made on the basis of positive chest imaging. Other studies have demonstrated these statistics, and the consensus is that chest CT is more sensitive at identifying sarcoid-related pulmonary changes. CT can identify subtle changes such as ground-glass opacities in stage 0 sarcoidosis before it is visible on CXR. While CXR is 90% sensitive for stage 1 pulmonary sarcoidosis, sensitivity falls when encompassing all stages \[[@CR15]\].

In patients with uveitis, CXR has been shown to be 68% sensitive \[[@CR16]\], while chest CT is 93% sensitive for diagnosing sarcoidosis \[[@CR17]\]. In patients with a negative CXR but high clinical suspicion of sarcoid uveitis, chest CT is 73% sensitive. The argument could be made that all patients with suspicion for sarcoid uveitis should undergo CT imaging rather than CXR. However, the monetary cost and radiation exposure make the topic controversial. Furthermore, we noted that 19 of the 204 patients in our study received a chest CT because of an equivocal finding on CXR and none of these patients were found to have any significant lung pathology. According to an online healthcare cost database \[[@CR18]\], the in-network cost of a chest CT for an insured patient is 35 times higher than that of a CXR. Additionally, a single chest CT delivers 70 times the radiation of one CXR \[[@CR19]\]. On the basis of this data, some physicians may consider screening with CXR and obtaining a chest CT only if negative, or instead being more selective in obtaining chest CT in the initial workup of uveitis. In our population this could mean a lower threshold for CT scan in black patients, with judicious use in other demographics. It should also be considered that a negative or indeterminate CXR may prompt a CT scan in some circumstances.

Serum ACE is 50% sensitive in our study which is consistent with prior studies on the sensitivity of ACE in diagnosing sarcoidosis (41--72%) \[[@CR20], [@CR21]\]. However, when taking into account all patients with or without positive chest imaging, sensitivity of ACE falls to 31% while specificity is 96%. Similarly, serum lysozyme had moderately low sensitivity in our study (60%) but a high negative predictive value (98%). This data suggests that serum ACE and lysozyme are poor screening tests but may be useful in ruling out the diagnosis of sarcoidosis in patients with uveitis. We did not obtain data regarding serum soluble interleukin-2 receptor levels because of the retrospective nature of our study, but more a recent study from 2017 has shown this to be useful \[[@CR22]\].

The utility of establishing a diagnosis of sarcoidosis should be considered. Thirty to forty percent of uveitis cases reveal no specific cause and are determined to be idiopathic \[[@CR23]--[@CR25]\]. However, this does not preclude these patients from receiving adequate treatment. The treatment regimen for a given case of uveitis is often unaffected by the final diagnosis, or lack thereof. One particular study showed there was no significant difference in relapse rates between patients with an associated diagnosis and those with idiopathic uveitis \[[@CR25]\]. Treatment of ocular sarcoidosis is not unlike certain other forms of uveitis, with the treatment regimen tailored to the extent and location of ocular inflammation. According to current pulmonology practices, systemic immunosuppressive therapy is not indicated for asymptomatic lung disease with stage 1 findings on CXR, as the majority of these cases resolve without treatment \[[@CR9], [@CR26]\].

On the other hand, inadequately treated sarcoidosis may lead to morbidity and mortality. A 2015 study showed that cardiac conduction defects may be detectable on electrocardiogram in patients with asymptomatic sarcoidosis \[[@CR27]\]. Han et al. \[[@CR28]\] suggested that chest CT and electrocardiogram be obtained in all undiagnosed cases with high clinical suspicion for sarcoid uveitis.

Limitations of our study include a retrospective analysis and a low incidence of sarcoid-related uveitis. Although chest CT may be more sensitive, our initial evaluation is, in general, CXR imaging. Additionally, a targeted approach to laboratory testing was done as outlined by others \[[@CR14]\].

Conclusion {#Sec5}
==========

The incidence of sarcoidosis was low in our study population. This translated to a low rate of discovery by CXR, and hence the utility of CXR as a diagnostic test is less useful when the incidence of the disease is low. Black patients are more likely to develop uveitis and sarcoidosis than other demographic groups, and the yield for sarcoid screening in these patients is significantly higher.
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